Droperidol is associated with reduced length of stay in the treatment of cannabinoid hyperemesis syndrome
We believe that droperidol may be considered as a first line treatment in patients with cannabinoid hyperemesis syndrome. Future studies should identify optimal dosing regimens using a randomized controlled trial design.
Authors
- Geoffrey S. Kelly (ORCID: https://orcid.org/0000-0002-8644-5558)
- G. Rodney Meeks
- Tim P. Moran
- Viral Doshi
- Bradley McCoul
Institutions
- Emory University (US)
Publication Details
- Journal
- Clinical Toxicology
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1080/15563650.2025.2516128
- Citations
- 1
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 1.39